1) Review advanced image processing and metabolic parameters in FDG-PET/CT. 2) Discuss non-FDG radiotracers and their potential applications in non-small cell lung cancer. 3) Illustrate the role of advanced PET/CT in case examples.
Assessment of non-small cell lung cancer with PET is typically performed using F-18 fluorodeoxyglucose (FDG). The uptake and retention of FDG by the tumor is taken to be a measure of metabolism, which in turn can provide useful information on staging, grading, and prognosis. Advances in the field of PET/CT imaging may provide additional information for the evaluation and care of patients with lung cancer. Advanced semi-quantitative analyses including total lesion glycolysis (TLG) and metabolic tumor volume (MTV) have been employed to capture additional information from FDG-PET/CT studies, which in some cases is additive to standard metabolic parameters such as SUVmax. New tracers are under development, with some nearing approval in the U.S. and elsewhere. These include tracers targeting proliferation, receptor expression, and protein catabolism, investigating molecular events and processes beyond glucose metabolism.
Rohren, E,
PET Imaging of Lung Cancer: Beyond Standard Metabolic Assessment. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL.
http://archive.rsna.org/2014/14000761.html
